Hepatocellular carcinoma treatment response: Imaging findings and criteria

doi:10.4329/wjr.v17.i10.108804

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 10

This Article

(65)

(37)

(0)

(1064)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Radiology

ISSN

1949-8470

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Radiol. Oct 28, 2025; 17(10): 108804
Published online Oct 28, 2025. doi: 10.4329/wjr.v17.i10.108804

Full Size Figure Download Figure

Figure 7 Hepatocellular carcinoma treated with trans-arterial radioembolization in a 60-year-old man with hepatitis C virus-related hepatic cirrhosis. A: On hepatic arterial phase (HAP) computed tomography (CT) obtained 3 months after treatment, hepatocellular carcinoma (HCC) shows persistent enhancement (arrow); B: On HAP CT obtained 6 months after start of treatment, HCC shows almost-complete disappearance of enhancement and decrease in size.

Citation: Agnello F, Taibbi A, Galia M, Orlando A, Gagliardo C, Bartolotta TV. Hepatocellular carcinoma treatment response: Imaging findings and criteria. World J Radiol 2025; 17(10): 108804
URL: https://www.wjgnet.com/1949-8470/full/v17/i10/108804.htm
DOI: https://dx.doi.org/10.4329/wjr.v17.i10.108804

Agnello F, Taibbi A, Galia M, Orlando A, Gagliardo C, Bartolotta TV. Hepatocellular carcinoma treatment response: Imaging findings and criteria. World J Radiol 2025; 17(10): 108804 [PMID: 41180907 DOI: 10.4329/wjr.v17.i10.108804]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.